Nathan Lawrentschuk

Also affiliated with The Royal Melbourne Hospital, The University of Melbourne, Peter MacCallum Cancer Centre, Prostate Cancer Research

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 2 papers. Top paper: “Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds”.

Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds

Current Opinion in Urology(2009)10.1097/mou.0b013e328316c357

N/A

1.6DataRank · unranked

22 citations

Nathan Lawrentschuk, Damien M Bolton, Peter Wong

Lymphovascular Invasion at the Time of Radical Prostatectomy Adversely Impacts Oncological Outcomes

Cancers(2023)10.3390/cancers16010123

N/A

0.385DataRank · unranked

12 citations

Marc A. Furrer, Clancy J. Mulholland, Andreas Katsios, Christopher Soliman, Nathan Lawrentschuk +15 more